Adiponectin Receptor 1 (ADIPOR1) rs1342387 Polymorphism and Risk of Cancer: a Meta-analysis

  • Yu, Li-Xiang (Department of Breast Diseases, The Second Hospital of Shandong University) ;
  • Zhou, Nan-Nan (Department of Aged Cardiovascular Diseases, Shandong Provincial Hospital Affiliated to Shandong University) ;
  • Liu, Li-Yuan (Epidemiology Institute, School of Public Health, Shandong University) ;
  • Wang, Fei (Department of Breast Diseases, The Second Hospital of Shandong University) ;
  • Ma, Zhong-Bing (Department of Breast Diseases, The Second Hospital of Shandong University) ;
  • Li, Jie (Nursing Psychology, School of Nursing, Shandong University) ;
  • Yu, Zhi-Gang (Department of Breast Diseases, The Second Hospital of Shandong University)
  • Published : 2014.10.11


Many studies have indicated possible associations between a polymorphism of adiponectin receptor 1 (ADIPOR1) rs1342387 and risk of cancer, but contradictory results have been reported. The main aim of this study was to draw a reliable conclusion about the relationship between the rs1342387 polymorphism and cancer incidence, by conducting a literature search of Pubmed, Embase, Wanfang and Cochrane libraries. Eleven studies including 3, 738 cases and 4, 748 controls were identified in this meta-analysis. The ADIPOR1 rs1342387 polymorphism was associated with risk of colorectal cancer for all genetic comparison models (GG vs AA, OR: 1.44, 95%CI: 1.21-1.70; G carriers vs A carriers, OR: 1.23, 95%CI: 1.11-1.36; dominant model, OR: 1.28, 95%CI: 1.10-1.49 and recessive model, OR: 1.31, 95%CI: 1.12-1.55). Stratified by ethnicity, the rs1342387 polymorphism was significantly associated with risk of colorectal cancer in Asian ancestry for all genetic comparison models (GG vs AA, OR: 1.56, 95%CI: 1.26-1.92; G carriers vs. A carriers OR: 1.30, 95%CI: 1.18-1.43; dominant model OR: 1.31, 95%CI: 1.08-1.60 and recessive model OR: 1.44, 95%CI: 1.26-1.64), but not in Caucasian or mixed (Caucasian mainly) groups. In summary, the ADIPOR1 rs1342387 polymorphism is significantly associated with risk of colorectal cancer among individuals of Asian ancestry.


Supported by : Shandong University


  1. An W, Bai Y, Deng SX, et al (2012). Adiponectin levels in patients with colorectal cancer and adenoma: a metaanalysis. Eur J Cancer Prev, 21, 126-33.
  2. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS (2007). Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr, 86, s858-66.
  3. Beebe-Dimmer JL, Zuhlke KA, Ray AM, et al (2010). Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African Americans. Prostate Cancer Prostatic Dis, 13, 362-8.
  4. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.
  5. Crimmins NA, Martin LJ (2007). Polymorphisms in adiponectin receptor genes ADIPOR1 and ADIPOR2 and insulin resistance. Obes Rev, 8, 419-23.
  6. Dalamaga M, Diakopoulos KN, Mantzoros CS (2012). The role of adiponectin in cancer: a review of current evidence. Endocr Rev, 33, 547-94.
  7. Finucane MM, Stevens GA, Cowan MJ, et al (2011). National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet, 377, 557-67.
  8. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7, 177-88.
  9. Egger M, Davey SG, Schneider M, et al (1997). Bias in metaanalysis detected by a simple, graphical test. BMJ, 315, 629-34.
  10. Fan HJ, Wen ZF, Xu BL, et al (2013). Three adiponectin rs1501299G/T, rs822395A/C, and rs822396A/G polymorphisms and risk of cancer development: a metaanalysis. Tumour Biol, 34, 769-78.
  11. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
  12. He B, Pan Y, Zhang Y, et al (2011). Effects of genetic variations in the adiponectin pathway genes on the risk of colorectal cancer in the Chinese population. BMC Med Genet, 12, 94.
  13. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
  14. Inoue M, Tsugane S (2012). Insulin resistance and cancer: epidemiological evidence. Endocr Relat Cancer, 19, 1-8.
  15. Ishikawa M, Kitayama J, Yamauchi T, et al (2007). Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci, 98, 1120-7.
  16. Joshi RK, Lee SA (2014). Obesity related adipokines and colorectal cancer: a review and meta-analysis. Asian Pac J Cancer Prev, 15, 397-405.
  17. Kim AY, Lee YS, Kim KH, et al (2010). Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2- mediated AMPK activation. Mol Endocrinol, 24, 1441-52.
  18. Kaklamani V, Yi N, Zhang K, et al (2011). Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk. Metabolism, 60, 1234-43.
  19. Kaklamani VG, Sadim M, Hsi A, et al (2008). Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res, 68, 3178-84.
  20. Kaklamani VG, Wisinski KB, Sadim M, et al (2008). Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA, 300, 1523-31.
  21. Liu L, Zhong R, Wei S, et al (2011). Interactions between genetic variants in the adiponectin, adiponectin receptor 1 and environmental factors on the risk of colorectal cancer. PLoS One, 6, 27301.
  22. Liu LY, Wang M, Ma ZB, et al (2013). The role of adiponectin in breast cancer: a meta-analysis. PLoS One, 8, 73183.
  23. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  24. Mather KJ, Christophi CA, Jablonski KA, et al (2012). Common variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/2), adiponectin concentrations, and diabetes incidence in the Diabetes Prevention Program. Diabet Med, 29, 1579-88.
  25. Nordmann AJ, Kasenda B, Briel M (2012). Meta-analyses: what they can and cannot do. Swiss Med Wkly, 142, 13518.
  26. Ou Y (2012). The association of polymorphisms on ADIPOQ and ADIPORl with risk and prognosis of cancer. second military medical university, shanghai, China, 2012. 24-62
  27. Siitonen N, Pulkkinen L, Mager U, et al (2006). Association of sequence variations in the gene encoding adiponectin receptor 1 (ADIPOR1) with body size and insulin levels. The Finnish Diabetes Prevention Study. Diabetologia, 49, 1795-805.
  28. Ouchi N, Kihara S, Arita Y, et al (2000). Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NFkappaB signaling through a cAMP-dependent pathway. Circulation, 102, 1296-301.
  29. Paz-Filho G, Lim EL, Wong ML, et al (2011). Associations between adipokines and obesity-related cancer. Front Biosci (Landmark Ed), 16, 1634-50.
  30. Renehan AG, Tyson M, Egger M, et al (2008). Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet, 371, 569-78.
  31. Tsuchida A, Yamauchi T, Ito Y, et al (2004). Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem, 279, 30817-22.
  32. Tsukada T, Fushida S, Harada S, et al (2011). Adiponectin receptor-1 expression is associated with good prognosis in gastric cancer. J Exp Clin Cancer Res, 30, 107.
  33. Vucenik I, Stains JP (2012). Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann N Y Acad Sci, 1271, 37-43.
  34. Wells GA, Shea B, O'Connell D, et al (2000). The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [cited 28 October 2013]. Available from
  35. Xu Y, He B, Pan Y, et al (2013). The roles of ADIPOQ genetic variations in cancer risk: evidence from published studies. Mol Biol Rep, 40, 1135-44.
  36. Yang Y, Zhang F, Ding R, et al (2013). ADIPOQ gene polymorphisms and cancer risk: a meta-analysis. Cytokine, 61, 565-71.
  37. Zhang Y, Feng Q, Liu C, et al (2012). Relationship between polymorphism sites of adiponection and it's receptor gene and the susceptibility of colorectal cancer. J Jiangsu University, 336-41.
  38. Zhou, W, Liu, Y, Zhong, DW (2013). Adiponectin (ADIPOQ) rs2241766 G/T polymorphism is associated with risk of cancer: evidence from a meta-analysis. Tumour Biol, 34, 493-504.
  39. Ziemke F, Mantzoros CS (2010). Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr, 91, 258-61.

Cited by

  1. Three ADIPOR1 Polymorphisms and Cancer Risk: A Meta-Analysis of Case-Control Studies vol.10, pp.6, 2015,
  2. Circulating Levels of Adipocytokines as Potential Biomarkers for Early Detection of Colorectal Carcinoma in Egyptian Patients vol.16, pp.16, 2015,
  3. Association of ADIPOQ and ADIPOR variants with risk of colorectal cancer: A meta-analysis vol.37, pp.2, 2017,